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  32 
Abstract 33 
 34 
Maternal asthma during pregnancy adversely affects pregnancy outcomes but the underlying 35 
mechanisms are unknown. Identification of the cause/s, and the ability to evaluate 36 
interventions, is limited by the lack of an appropriate animal model. We aimed to characterise 37 
maternal and fetal effects in a sheep model of allergic asthma. Immune and airway functions 38 
were studied in singleton-bearing ewes, either sensitised before pregnancy to house dust mite 39 
(HDM, allergic, n=7) or non-allergic (control, n=5), and then subjected to repeated airway 40 
challenges with HDM (allergic group) or saline (control group) throughout gestation. 41 
Maternal lung, fetal and placental phenotypes were characterised at 140 ± 1 d gestational age 42 
(term ~147 d). The eosinophil influx into lungs was greater after HDM challenge in allergic 43 
ewes than after saline challenge in control ewes before mating (P<0.01) and in late gestation 44 
(P<0.001). Airway resistance increased throughout pregnancy in allergic (P<0.05) but not 45 
control ewes, consistent with airway smooth muscle accumulation in allergic ewes (P<0.01). 46 
Maternal allergic asthma decreased relative fetal weight (-12%, P=0.038) and altered 47 
placental morphology. Expression of surfactant protein B mRNA was 48% lower in fetuses 48 
from allergic ewes than controls (P=0.045), with a similar trend for surfactant protein D (-49 
50%, P=0.053). Thus, allergic asthma in pregnant sheep inhibits fetal growth and lung 50 
development consistent with observations from human pregnancies. Preconceptional allergen 51 
sensitisation and repeated airway challenges in pregnant sheep therefore provides an animal 52 
model to identify mechanisms of altered fetal development and adverse pregnancy outcomes 53 
caused by maternal asthma in pregnancy. 54 
  55 
Introduction 56 
 57 
Asthma is a chronic inflammatory disease of the airways, characterised by reversible airflow 58 
limitation or bronchial hyper-responsiveness resulting in respiratory symptoms such as 59 
wheezing, shortness of breath and coughing. Asthma has a variety of causes and is 60 
phenotypically diverse, but allergic sensitisation is considered the most common initiating 61 
factor (Bousquet et al., 2010). In women of reproductive age the prevalence of asthma is 62 
higher than in the general population: 12% (95% CI: 9.7-14.3%) of females aged 15-29 years 63 
and 10.8% (95% CI: 9.4-12.3%) of women aged 30-44 years have asthma (Australian Bureau 64 
of Statistics, 2012). Thus, asthma is one of the most common chronic diseases to affect 65 
pregnant women. Maternal asthma is a well-established risk factor for numerous adverse 66 
pregnancy outcomes including preeclampsia (RR 1.54; 95% CI 1.32-1.81), preterm birth (RR 67 
1.41; 95% CI 1.22-1.61), intrauterine growth restriction (RR 1.46; 95% CI 1.22-1.75) 68 
(Murphy et al., 2011), peripartum maternal cardiomyopathy (8% vs 2%; P<0.0001) (Kao et 69 
al., 2013) placental abruption, and antenatal or postnatal haemorrhage (Clifton et al., 2009; 70 
Hodyl et al., 2014). In addition to adverse pregnancy outcomes, maternal asthma is a major 71 
risk factor for poor neonatal outcome. Analysis of a large retrospective cohort of over 72 
200,000 singleton pregnancies demonstrated that infants of asthmatic mothers were at 73 
increased risk of hospitalisation (RR 1.50; 1.03, 2.20) and this increase in risk was evident in 74 
both term and preterm neonates (Hodyl et al., 2014). Risks of neonatal respiratory distress 75 
syndrome (RDS) and transient tachypnea of the newborn (TTN) are also elevated in infants 76 
of mothers who had asthma during pregnancy (Mendola et al., 2014), suggesting that 77 
maternal asthma impairs fetal lung development. 78 
 79 
Asthma worsens during pregnancy in over 50% of women (Murphy et al., 2005). Asthma 80 
exacerbation during pregnancy (defined as any asthma-related event that involves a hospital 81 
admission, an unscheduled doctor visit, a course of oral steroids, an increase in medication 82 
use and/or decreased peak expiratory flow rate is the most significant risk factor for fetal 83 
morbidity and mortality in progeny of asthmatic mothers (Murphy et al., 2005). Such 84 
exacerbations are common, particularly in women whose asthma is more severe, occurring in 85 
8%, 47% or 65% of pregnant women with mild, moderate or severe asthma, respectively 86 
(Murphy et al., 2005). Exacerbations can occur at any time during gestation but are most 87 
likely to occur in the second and third trimesters, between weeks 17 and 34, with peak 88 
incidence around the 25
th
 week of gestation (Murphy et al., 2005; Murphy et al., 2006). 89 
  90 
Despite a well-established association between maternal asthma and adverse pregnancy 91 
outcomes, knowledge of the mechanisms underlying these effects remains limited, largely 92 
because investigations have been restricted to clinical studies. Understanding the relative 93 
contributions of asthma severity, exacerbations and treatment to adverse pregnancy, fetal and 94 
neonatal outcomes from investigations of clinical cohorts is difficult since it is ethically 95 
impossible to randomise women to no treatment for their asthma during pregnancy. 96 
Mechanistic information to guide the development of targeted therapies to prevent adverse 97 
outcomes is often impossible to obtain from humans. Therefore, there is need for an animal 98 
model of maternal asthma in which mechanistic studies can be undertaken. Sheep have long 99 
been used to study pregnancy, fetal development and perinatal physiology, and a number of 100 
medical interventions now routinely used in contemporary obstetrics and neonatology were 101 
translated into practice from sheep experiments (Liggins, 1969; Gunn et al., 1997; Roelfsema 102 
et al., 2004). 103 
 104 
It is possible to induce allergy and asthma in non-pregnant sheep using HDM allergen 105 
(Bischof et al., 2003; Snibson et al., 2005; Bischof et al., 2008), which results in a similar 106 
lung phenotype to human asthma (James et al., 2012), with eosinophil infiltration, 107 
progressive loss of lung function, increased airway collagen deposition and thickening of 108 
bronchial smooth muscle (Bischof et al., 2003; Snibson et al., 2005; Meeusen et al., 2009). 109 
We hypothesised that sensitisation to HDM and airway allergen challenges prior to mating 110 
would similarly establish an asthmatic phenotype in pregnant sheep, and that this would have 111 
effects on pregnancy and fetal development consistent with observations from human 112 
pregnancy. The aim of the present study was to develop a sheep model of asthma in 113 
pregnancy that reproduces maternal and fetal responses to maternal asthma in human 114 
pregnancy. This will provide an experimental model in which to answer mechanistic 115 
questions and evaluate interventions, not possible in clinical or epidemiological human 116 




Animals and Experimental design: 121 
All experimental animal procedures were approved by the Animal Ethics Committees of 122 
Monash University (MARP/2013/133) and the University of Adelaide (M-2014-126), and 123 
were conducted in accordance with Australian guidelines (National Health and Medical 124 
Research Council of Australia, 2013).  125 
 126 
Merino ewes (1-2 years of age) were allocated randomly to either non-immunised control 127 
(n=9) or sensitised (n=31) groups (Figure 1). Sheep in the sensitised group were immunised 128 
with HDM using four subcutaneous (s.c.) injections of 50 μg of solubilised HDM extract 129 
(Dermatophagoides pteronyssinus; CSL Ltd, VIC, Australia) in sterile 0.9% NaCl, and 130 
aluminium hydroxide as adjuvant (1:1), with injections given at 2 week intervals (Bischof et 131 
al., 2003). Peripheral blood was collected by venepuncture prior to the commencement of 132 
HDM immunisations and again 7 days (d) after the final immunisation, to determine HDM-133 
specific serum IgE levels and allergic status of immunised sheep; time-matched samples were 134 
collected from control sheep. HDM-specific IgE levels were determined in duplicate samples 135 
by ELISA, with optical density (OD) read at 450 nm (A450) (Bischof et al., 2003; Bischof et 136 
al., 2008). Of the 31 sensitised sheep, there were 17 that showed a two-fold or greater 137 
increase in IgE levels after HDM immunisation, and these were defined as allergic (Bischof 138 
et al., 2003).  139 
 140 
Allergic and control sheep then received weekly endoscopic airway challenges with HDM or 141 
saline, respectively (described below), for eight weeks before timed mating with Merino rams 142 
(Figure 1). Estrus was synchronised using intravaginal sponges containing 300 mg of the 143 
synthetic progestagen flugestone acetate (Eazi-breed CIDR device, Zoetis Australia Pty Ltd, 144 
NSW, Australia) for a 12-d period. Mating dates were recorded, and pregnancy status and 145 
fetal number were determined by ultrasound at 40-45 d gestational age (dGA; term ~147 146 
dGA).  147 
 148 
Throughout pregnancy, allergic sheep received endoscopic airway challenges with HDM 149 
every two weeks, and non-allergic sheep received endoscopic airway challenges with saline 150 
every four weeks (Figure 1). All animals were housed and handled as one group. Sheep were 151 
housed outdoors in small paddocks during allergen sensitisation and airway challenges until 152 
approximately 90-100 dGA. During this period, sheep grazed natural pastures and were 153 
supplemented with lucerne hay. Pregnant sheep were housed indoors in individual pens for 154 
the remainder of the experimental period, in a facility with a 12 h:12 h dark-light cycle, and 155 
were fed 0.8-1.0 kg lucerne chaff and 0.85 kg ewe and lamb pellets (Rumevite, Ridley 156 
AgriProducts, VIC, Australia) daily, with water available ad libitum. 157 
 158 
Outcomes were studied in only singleton-bearing ewes from each group. Singleton-bearing 159 
non-allergic animals (control, n=9) included 5 sheep from the non-sensitised group plus 4 160 
sheep from the sensitised group who did not show increases in IgE after the sensitisation 161 
protocol, and the allergic group consisted of 11 singleton-bearing sheep (Figure 1).  162 
 163 
Catheterisation of ewes and fetuses 164 
Surgery was performed at 96-108 dGA (102 ± 1 dGA, mean ± SEM) on control (n=9) and 165 
allergic (n=11) ewes identified by ultrasound as pregnant with singleton fetuses (Figure 1). 166 
Food was withheld for 24 h prior to surgery, while drinking water remained unrestricted. 167 
Prophylactic antibiotics (1g ampicillin sodium; Aspen Pharmacare Australia, Australia) were 168 
administered intravenously (i.v.) to the ewe on the day of surgery. General anaesthesia was 169 
induced by i.v. injection of 15-20 mg/kg sodium thiopentone (Pentothal; Boehringer-170 
Ingelheim, Australia) and maintained by inhalation of 1.5-3% isoflurane (Delvet, Ceva, 171 
Glenorie, NSW, Australia).  Indwelling catheters were placed into the maternal and fetal 172 
carotid arteries and jugular veins and amniotic fluid (Moss et al., 2003; Westover & Moss, 173 
2012) to enable maternal physiological responses to airway challenges to be recorded and 174 
fetal well-being to be monitored. 175 
 176 
Endoscopic airway challenges and characterisation of maternal immune responses 177 
For endoscopic airway challenges, sheep were restrained unsedated in a custom-designed 178 
body harness and a flexible fibre-optic endoscope (Model FG-16X; Pentax Ltd, VIC, 179 
Australia) was inserted into the lung via the nasal passage (Bischof et al., 2003). In allergic 180 
ewes, 5 ml of 100 μg/ml HDM extract (in sterile saline) was delivered as a bolus infusion into 181 
each of the right and left caudal lobes of the lung, whilst control non-allergic ewes were 182 
similarly challenged with the same volume of saline (Bischof et al., 2003; Meeusen et al., 183 
2009). 184 
 185 
Bronchoalveolar lavage (BAL) fluid samples were collected from the right caudal lobe before 186 
the first airway challenge, and then prior to (0 h) and 48 h after airway allergen challenges 187 
(Bischof et al., 2003) conducted pre-mating, at mid pregnancy (50-65 dGA; 55 ± 1 dGA) and 188 
in late pregnancy (118-132 dGA, 123 ± 1 dGA). Challenges at mid and late pregnancy were 189 
delivered as aerosols (see below). BAL cells were fixed and stained in Turk’s solution 190 
(Merck Millipore, VIC, Australia) and total white blood cells counted using a 191 
haemocytometer. Cytospots of BAL samples were prepared on glass microscope slides, 192 
stained with Kwik-Diff (Thermo Electron Corp., USA) and white blood cell subpopulations 193 
counted using light microscopy.   194 
 195 
White blood cell subpopulations were counted in all animals, as detailed above, in maternal 196 
blood smears collected immediately before and 24 h and 48 h after challenge in late 197 
pregnancy. 198 
 199 
Characterisation of maternal lung function and blood pressure responses to aerosolised 200 
airway challenges  201 
Allergen-specific airway responses to HDM challenge in allergic sheep were measured at 202 
early (8-28 dGA; 19 ± 2 dGA), mid and late pregnancy (at the same ages as BAL collection 203 
as detailed above). Airway responses to saline challenge were measured in early and late 204 
pregnancy in control sheep. Similar to airway challenges above, sheep were restrained, 205 
unsedated, in a custom-made sling. Lung function was assessed following aerosolised HDM 206 
or saline airway challenges. A solution of HDM extract (100 μg/ml) for allergic sheep, or 207 
saline for control sheep, was nebulised for 15 min at 20 breaths per minute (bpm) 208 
(Koumoundouros et al., 2006). In order to measure lung resistance (RL), oesophageal and 209 
tracheal catheters were placed via the nostrils for measurement of extra- and intra-thoracic 210 
pressures, respectively. A fibre-optic endoscope was used to guide placement of the catheters, 211 
with the tracheal catheter being inserted via a cuffed endotracheal (ET) tube. The ET tube 212 
placed through the nostril into the trachea enabled a closed respiratory loop to be established 213 
for airway delivery and lung function measures. The aerosol delivery system consisted of a 214 
breathing circuit, a Harvard Ventilator (ventilator Model 55-0723; Harvard 289 Apparatus, 215 
MA, USA), Rapid Flow
TM
 Nebulizer bowl (Allersearch Laboratories, Oakhurt USA) and 216 
Vitalair Rapid Nebulizer Pump (Gardner Denver Thomas, Inc., Sheboygan, USA). The 217 
nebuliser was connected to the end of the breathing circuit via a T-piece to the ET tube, 218 
during aerosol challenges only, with the ventilator set at 20 breaths per minute, inspiratory 219 
time 1.5 s, and a tidal volume (VT) of 300 mL. The oesophageal and tracheal catheters were 220 
connected to differential pressure transducers (GE Druck, ThermoFisher Scientific, Scoresby, 221 
VIC, Australia), recorded via LabChart
TM
 software (ADInstruments, Bella Vista, NSW, 222 
Australia), and RL was derived from breath-by-breath analysis of intra- and extra-thoracic 223 
pressures for a period of 25 min after aerosol challenge (Koumoundouros et al., 2006).   224 
 225 
Post-mortem and tissue collection  226 
Ewes were humanely killed at 140 ± 1 dGA by i.v. administration of an overdose of sodium 227 
thiopentone (Thiobarb, Jurox Pty Ltd, Rutherford, NSW, Australia). The uterus was removed 228 
by hysterectomy, amniotic fluid sampled, and the fetus removed and weighed. Maternal and 229 
fetal lung, heart, liver, kidneys, spleen, brain and fat depots (perirenal, retroperitoneal and 230 
omental), were dissected and weighed. Visceral fat weight was calculated as the sum of 231 
omental, retroperitoneal and perirenal fat depot weights. Maternal lungs and heart were 232 
processed as described below. All placentomes were removed from the endometrium, 233 
individually weighed and scored for phenotype (Type A, B, C or D) (Vatnick et al., 1991).  234 
 235 
Maternal lung structure 236 
Tissue was sampled from the left caudal lobe of the maternal lung, fixed in 4% 237 
paraformaldehyde (PFA) and processed for embedding in paraffin. Consecutive tissue 238 
sections cut at 4 µm were stained with haematoxylin and eosin (H&E), Masson’s trichrome 239 
or immunostained for airway mast cells (Snibson et al., 2005; Bischof et al., 2008). To assess 240 
airway wall remodelling in asthmatic sheep, collagen and smooth muscle area contents of the 241 
airway wall were determined by digital colour analysis of Masson’s trichrome-stained 242 
histological sections (Snibson et al., 2005). Digital images were scanned using an Aperio 243 
Image Capture device and Imagescope
TM
 software (Leica Biosystems Imaging Inc., Vista, 244 
CA, USA). Image analysis of 5-10 bronchioles and small bronchi, ranging from 200 to 2000 245 
µm in diameter (calculations based on airway basement membrane perimeter), were 246 
performed on Masson’s trichrome-stained lung sections using FIJITM Image-J software 247 
(Schindelin et al., 2012), with all measurements standardised to airway basement membrane 248 
(BM) length to adjust for airway size (Snibson et al., 2005). Lung tissues immunostained for 249 
tryptase
+
 mast cells were scanned as above and total number of stained cells were counted in 250 
10 scanned images of lung parenchyma (presented as cells per mm
2
 lung parenchyma) and in 251 
separate counts around the airway wall of 5-10 bronchioles and small bronchi (total and 252 
degranulated mast cells per BM length, as detailed above). 253 
 254 
Maternal heart measurements and gene expression 255 
The heart was weighed, dissected, and each ventricular free wall was weighed separately. A 256 
sample of the left ventricular free wall was snap frozen in liquid nitrogen. RNA was isolated 257 
from samples of the left ventricular free wall (~50 mg) of each ewe, and cDNA was 258 
synthesised as previously described (Wang et al., 2011).  259 
 260 
The reference genes (beta actin, hypoxanthine phosphoribosyltransferase 1 and tyrosine 3-261 
monooxygenase (YWAHZ)) were chosen (Duffield et al., 2009; Passmore et al., 2009; Wang 262 
et al., 2013; Hellemans & Vandesompele, 2014) based on expression analysis using the 263 
geNorm component of the qBase (Biogazelle, Zwinjnaarde Belgium) relative quantification 264 
analysis software (Hellemans et al., 2007) because their expression was stable across samples 265 
(M value, factor=0.3-0.4 (Vandesompele et al., 2002; Soo et al., 2012; Hellemans & 266 
Vandesompele, 2014)). The relative expression of mRNA transcripts of molecules involved 267 
in physiological hypertrophy (IGF1, IGF1R and IGF2 (Gentili et al., 2009; Zhang et al., 268 
2010)), pathological hypertrophy (ANP, BNP, IGF2R and AT1R (Lie et al., 2013; Zhang et 269 
al., 2013; Lie et al., 2014)), cortisol availability (GR, MR, 11βHSD1 and 11βHSD2 (Gentili 270 
et al., 2009)), inflammation (TNF and IL1β), fibrosis (TGFβ, collagen type II, MMP 2, 271 
TIMP 1, TIMP 2 and TIMP 3 (Zhang et al., 2010; Wang et al., 2015)), proliferation (PCNA 272 
and Ki67), reactive oxygen species (HO1) and glucose and fatty acid uptake (Glut1, Glut4, 273 
FATP1 and CPT1 (Gentili et al., 2009; Wang et al., 2013; Nicholas et al., 2014)) were 274 
measured by qRT-PCR (Table 1) using Fast SYBR® Green Master Mix (Applied 275 
Biosystems, CA, USA) on a ViiA7 Fast Real-time PCR system (Applied Biosystems) as 276 
previously described (Wang et al., 2011; Soo et al., 2012; McGillick et al., 2013). 277 
 278 
Fetal lung phenotype 279 
Tissue was sampled from the left caudal lobe of the fetal lung, avoiding large airways and 280 
blood vessels, and snap frozen in liquid nitrogen. Total RNA was extracted and qRT-PCR 281 
was used to measure gene expression under optimized primer-specific conditions as 282 
described previously (Westover & Moss, 2012), using 1 µg of RNA with Superscript III First 283 
Strand Synthesis system kit for real-time PCR, as specified by the manufacturer (Life 284 
Technologies). Gene primers for surfactant protein (SP) -A, -B, -C and -D were as previously 285 
published (Westover & Moss, 2012), and Rps29 rRNA was used as the reference gene 286 
because its levels were stable across fetal lung samples. Rps29 was amplified using the 287 
following primers (F: CAGGGTTCTCGCTCTTGC  R: ACTGGCGGCACATATTGAG). 288 
Messenger RNA levels were normalised to expression of the reference gene Rps29 rRNA for 289 
each fetus, and gene expression in fetuses from the allergic group was expressed relative to 290 
the mean mRNA abundance for that gene in the control fetuses.  291 
 292 
  293 
Statistical analyses 294 
Continuous outcomes in control and allergic sheep were compared by one-way ANOVA.  295 
Changes in RL were analysed by repeated measures ANOVA for effects of gestational age 296 
and treatment. Immune cell percentages in BAL pre- and post-challenge, in allergic and 297 
control sheep and across gestational ages were compared by Holm-Sidak’s multiple 298 
comparisons test. Relative mRNA levels between groups were compared using non-paired t-299 
tests. Statistical tests were performed using SPSS version 21 and data are presented as mean 300 




Maternal immune responses to challenge 305 
Prior to mating and in late pregnancy, BAL samples collected before the airway challenge (0 306 
h) from control and allergic sheep, comprised similar proportions of macrophages, 307 
lymphocytes, neutrophils and eosinophils (Figure 2). In allergic sheep, the proportion of 308 
eosinophils in BAL increased markedly 48 h after airway allergen challenge at each time 309 
point (each P<0.01), whilst eosinophil proportions did not rise after saline challenge in 310 
control sheep (Figure 2). In late pregnancy, macrophages comprised a greater proportion of 311 
immune cells in BAL collected pre-challenge, in allergic compared to control sheep (P<0.05, 312 
Figure 2). After challenge in late pregnancy, eosinophils comprised a greater proportion of 313 
immune cells in BAL and macrophages comprised a lower proportion of immune cells in 314 
BAL, in allergic compared to control sheep (each P<0.001, Figure 2). In allergic sheep in late 315 
pregnancy, the proportions of eosinophils increased in post-challenge compared to pre-316 
challenge BAL samples (P<0.001), whilst the proportions of macrophages decreased 317 
(P<0.001, Figure 2). The abundance of neutrophils in BAL was lower in pregnant compared 318 
to non-pregnant sheep overall (P<0.05, Figure 2). 319 
 320 
There was no difference in the numbers or proportions (%) of immune cell types in peripheral 321 
blood when examined prior to airway challenge in control versus allergic sheep before 322 
mating or in late pregnancy (data not shown). In allergic sheep in late pregnancy, there was a 323 
decline in the percentage of lymphocytes and monocytes, and a corresponding increase in 324 
eosinophils, in peripheral blood at 48 h after airway allergen challenge compared to pre-325 
challenge, but these proportions did not change with gestation in control sheep (data not 326 
shown).   327 
Maternal physiological responses to challenge  328 
There was no change in RL after saline challenge in controls in early or late gestation (Figure 329 
3).  HDM allergen challenge increased RL (relative to baseline RL) throughout gestation in 6 330 
of the 7 allergic sheep. The increase in RL in allergic sheep was greater in mid- and late-331 
pregnancy compared to early-pregnancy (Figure 3, P<0.05). In late pregnancy, airway 332 
responses to HDM challenge in allergic sheep were greater than the response to saline 333 
challenge in control sheep (Figure 3, P<0.01).  334 
 335 
Maternal outcomes at post-mortem 336 
Morphometric image analysis of maternal lung revealed significant increases in airway 337 
smooth muscle accumulation around the airways in allergic compared to control pregnant 338 
sheep, without significant changes in collagen deposition (P=0.056, Figure 4). Chronic HDM 339 
challenge of the airways in allergic pregnant sheep did not alter total mast cell numbers 340 
within the parenchyma and airway wall (Figure 4 E-F). However, there was a trend to greater 341 
numbers of degranulated mast cells within the airway walls in allergic compared to control 342 
pregnant sheep (controls: 0.15 ± 0.03 cells/mm BM; allergic 0.72 ± 0.29 cells/mm BM, 343 
P=0.093). 344 
 345 
Maternal body weight and absolute and relative organ weights did not differ between control 346 
and allergic sheep (Table 2, Figure 5A). Maternal cardiac expression of genes involved in 347 
physiological and pathological hypertrophy, cortisol availability, inflammation, fibrosis, 348 
proliferation, glucose uptake and reactive oxygen stress also did not differ between groups 349 
(Table 3). 350 
 351 
Placental and fetal outcomes at post-mortem 352 
Total placental weight, the number of placentomes and average placentome weight did not 353 
differ between groups (Table 4), but there were differences in placental phenotype. Whilst 354 
placentae from allergic ewes had similar absolute numbers of Type A (P=0.070), Type B 355 
(P=0.076) and Type C (P=0.073) placentomes (Figure 6A) compared to placentae of control 356 
ewes, Type B (P=0.037) and Type C (P=0.047) placentomes comprised greater proportions 357 
of total placentome numbers in the allergic group (Figure 6B). Additionally, the total weight 358 
of Type A placentomes was lower in placentae from allergic than in those from control ewes 359 
(Figure 6C). 360 
 361 
Absolute measures of fetal weight (-10% in allergic cf. control group) and size did not differ 362 
between treatments (Table 2, Figure 5B). However, fetal weight relative to maternal weight 363 
was 12% lower in the allergic group (P=0.038, Figure 5C). The singleton fetuses collected at 364 
post-mortem comprised 2 males and 3 females from control ewes, and 3 males and 4 females 365 
from allergic ewes. 366 
 367 
Maternal allergy decreased fetal lung gene expression of SP-B (P=0.045, Figure 7), and this 368 
also approached significance for SP-D expression (P=0.053, Figure 7). Expression of SP-A 369 




We have established a sheep model of maternal asthma in pregnancy, which demonstrates 374 
effects on fetal growth and development consistent with effects of maternal asthma in 375 
humans. Fetal body weight (relative to maternal weight) was 12% lower in asthmatic sheep 376 
pregnancies compared to controls, consistent with the magnitude of fetal growth restriction 377 
observed in the presence of maternal asthma in human pregnancy (Murphy et al., 2011; 378 
Namazy et al., 2013; Mendola et al., 2014). Placental phenotype in late pregnancy was 379 
altered, consistent with accelerated maturation of the placenta (Alexander, 1964), suggesting 380 
placental adaptation to compensate for impaired nutrient and/or oxygen supply in asthmatic 381 
pregnancies. Maternal asthma also decreased expression of surfactant proteins in fetal lung, 382 
which would be expected to impair neonatal lung function. These data provide novel insights 383 
into mechanisms underlying the association of maternal asthma with greater risks of 384 
respiratory distress syndrome (RDS) and transient tachypnoea of the newborn (TTN) in 385 
human babies (Mendola et al., 2014).  386 
 387 
Similar to our previous work in non-pregnant sheep (Bischof et al., 2003; Snibson et al., 388 
2005; Meeusen et al., 2009), 55% of animals were responsive to HDM sensitisation, showing 389 
elevation of HDM-specific IgE. Our work shows that conception rates are not affected by 390 
HDM sensitisation. These sheep subsequently exhibited symptoms consistent with allergic 391 
asthma, including an increase in systemic allergen-specific IgE levels, increased circulating 392 
and airway (BAL) eosinophils, decreased lung function and features of airway wall 393 
remodelling, but no changes in cardiac gene expression. Similar immune responses and 394 
structural changes are typical of the human asthmatic lung (James et al., 2012), though data 395 
from human pregnancies complicated by asthma is limited to lung function and circulating 396 
immune cells (Murphy et al., 2003; Osei-Kumah et al., 2010). In allergic sheep, the 397 
inflammatory response to HDM challenge in the lung worsened as pregnancy progressed, 398 
with increasing eosinophil induction in response to each challenge, and lung function 399 
continued to decline with repeated allergen exposures during pregnancy.  Direct comparisons 400 
of pregnant and non-pregnant animals during the same sensitisation and airway challenge 401 
regimes are needed to confirm whether this is a pregnancy-induced worsening of asthma, as 402 
occurs in human asthma during pregnancy (Murphy et al., 2005). 403 
 404 
Our findings of 10% and 12% reductions in absolute and relative fetal weights respectively in 405 
response to maternal allergic asthma is consistent with findings in human studies. Numerous 406 
epidemiological analyses report that asthmatic mothers are at an increased risk of delivering a 407 
low birth weight infant,  in particular when the asthma is severe, poorly controlled or acute 408 
exacerbations are experienced during gestation (Murphy et al., 2003; Murphy et al., 2005; 409 
Murphy et al., 2006; Murphy et al., 2011; Namazy et al., 2013; Mendola et al., 2014). 410 
Several studies in human pregnancy indicate that the fetal response to maternal asthma is 411 
dependent on fetal sex. Thus, in the presence of maternal asthma, there is a ~12% reduction 412 
in female birth weight when compared to female neonates from non-asthmatic mothers, while 413 
there is no difference in birth weight of male infants overall (Murphy et al., 2003). Critically,  414 
if the mother experiences an exacerbation during pregnancy then birth weight of male fetuses 415 
is decreased dramatically, with an associated rise in the rates of intra-uterine growth 416 
restriction (IUGR), preterm deliveries and stillbirths, whilst exacerbations do not have any 417 
further impact on birth weight in females (Murphy et al., 2005). These findings suggest males 418 
and females respond differently to maternal asthma and implement different strategies in 419 
relation to growth. Other perinatal exposures, including experimentally-induced IUGR or 420 
preterm birth, maternal antenatal glucocorticoid treatment or hypoxia, and fetal interventions 421 
such as treatment with insulin-like growth factor 1, induce sex-specific acute and long-term 422 
responses in sheep (Owens et al., 2007; Gentili et al., 2009; Lumbers et al., 2009; De Matteo 423 
et al., 2010; Tang et al., 2010; Giussani et al., 2011; Wang et al., 2011; Miller et al., 2012; 424 
Wang et al., 2013; Wooldridge et al., 2014; Poudel et al., 2015). The current study was not 425 
powered to examine sex differences, and additional studies will be required to assess whether 426 
responses to maternal asthma are also sex-dependent in sheep and to determine the 427 
underlying mechanisms.   428 
  429 
We demonstrated a significant alteration in placental phenotype in the presence of maternal 430 
allergic asthma in this study. The increased proportion of Type B and C placentomes in the 431 
presence of maternal allergic asthma in sheep is suggestive of a more mature placental 432 
phenotype (Alexander, 1964). The shift towards Type B and Type C placentomes in response 433 
to maternal asthma in the present study is similar to the enhanced placental maturation 434 
observed in late gestation following interventions that reduce fetal growth in early gestation 435 
in sheep. For example, restriction of fetal nutrient supply by surgical reductions in uterine 436 
epithelial attachment sites before mating (and hence placentome number throughout 437 
pregnancy), increases the proportion of Type D placentomes in late gestation (Robinson et 438 
al., 1979; Poudel et al., 2015). Maternal or fetal hypoxia are also associated with a significant 439 
change in placentome distribution with fewer Type A and more Types B, C and D (Penninga 440 
& Longo, 1998). Maternal undernutrition in early-mid pregnancy (ewes fed 50% of 441 
requirements from 28 to 77 dGA) reduces the proportion of Type A and increases the 442 
proportion of Type B placentomes present near term in sheep (Heasman et al., 1998), and 443 
milder maternal undernutrition (ewes fed 85% of requirements for the first 70 d after mating) 444 
shifts placental phenotype from Type A towards Type D placentomes (Steyn et al., 2001). 445 
Thus, placental changes induced by maternal asthma likely represent an adaptation to 446 
increase placental transfer capacity and maintain fetal growth in the face of reduced oxygen 447 
supply or inflammation. The functional significance of these phenotypic changes is the 448 
subject of some debate and merits direct study; measures of cell number, vascularity and 449 
vasoreactivity are more closely related to placentome size than type (Vonnahme et al., 2008) 450 
and placental nutrient delivery did not correlate with the proportions of Types C and D 451 
placentomes in sheep near term (Ward et al., 2006). The change in placental phenotype 452 
observed in the present study might also alter prostaglandin production near term, as 453 
developmental changes in protein content of the rate-limiting enzyme for prostaglandin 454 
synthesis vary between placentome sub-types (Braun et al., 2011). However, we do not yet 455 
know whether this would decrease gestational age at spontaneous delivery, consistent with 456 
increased rates of preterm birth in human pregnancies complicated by asthma (Murphy et al., 457 
2011). Consistent with maternal asthma altering placental phenotype in the present study, 458 
maternal asthma is associated with increased risks of placental complications including 459 
placental abruption and placenta praevia in human pregnancies (Wang et al., 2014). 460 
 461 
Maternal allergic asthma in sheep also has effects on fetal lung development consistent with 462 
the increased risk of RDS and TTN in human neonates whose mothers have asthma, 463 
compared to the general population (Mendola et al., 2014). SP-B gene expression was 464 
reduced in fetuses from allergic pregnancies in the present study, with similar trends for SP-465 
A, -C and -D, suggesting delayed maturation of the pulmonary surfactant system. 466 
Surfactant deficiency is the principle cause of respiratory distress syndrome (RDS) and 467 
contributes to the pathogenesis of transient tachypnoea of the newborn (TTN, Moss, 2006; 468 
Machado et al., 2011). RDS and TTN are common complications of prematurity, but in 469 
infants from asthmatic mothers the risk is elevated even after adjustment for gestational age 470 
(Mendola et al., 2014). It has been speculated that associations between maternal asthma and 471 
risk of RDS and TTN might relate to genetic factors associated with asthma (Machado et al., 472 
2011), but our findings show that maternal allergic asthma per se impairs development of the 473 
fetal lungs.   474 
 475 
Our development and validation of this new and unique model of allergic asthma in 476 
pregnancy lays the foundation for future studies focussed on understanding mechanisms 477 
through which maternal asthma during pregnancy increases the risk of adverse pregnancy and 478 
neonatal outcomes. This model also provides the opportunity to test interventions that may 479 
prevent adverse outcomes of asthma in pregnancy, by evaluating treatment responses in the 480 
mother and fetus, and assessing the short and long term effects of asthma treatments on the 481 
offspring. A strength of this model is that fetal sheep can be instrumented for physiological 482 
studies throughout the final third of gestation. The establishment of this model of maternal 483 
allergic asthma in the sheep will therefore enable detailed fetal physiological responses to 484 
asthma, exacerbations, clinically-used treatments and novel interventions to be assessed in 485 
detail.    486 
 487 
  488 
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  711 
Table 1. Sequences of oligonucleotide primers used for quantitative real-time RT-PCR for 712 
maternal cardiac tissues. 713 
 714 
Accession no. Gene Forward (F) and reverse (R) primer sequences 
NM_001160026.1 
 
BNP F- CCTGCTTCTCCTCTTCTTGC 
R- TAGACGGTCCAACAGCTCCT 
X55152 TNF  F- ACACCATGAGCACCAAAAGC 
 
R- AGGCACCAGCAACTTCTGGA 
NM_001009465.2 IL1β F- TGCCTACGAACATGTCTTCCGTGA 
R- TGCTCTCTGTCCTGGAGTTTGCAT 
NM_001034494.1 PCNA F- ACTCCACTGTCTCCTACAGTAA 
 
R- CGATCTTGGGAGCCAAATAGT 
XM_005197116.1 Ki67 F- TCAGTGAGCAGGAGGCAGTA 
R- GGAAATCCAGGTGACTTGCT 
NM_001014912.1 HO 1 F- CTGGTGATGGCGTCTTTGTA 
R- CAGCTCCTCTGGGAAGTAGA 
  715 
Table 2. Maternal body and organ weights at post-mortem. 716 
 717 
 Control (n=5) Allergic (n=7) 
Body weight (kg) 38.9 ± 2.1 39.6 ± 1.4 
Lung (g) 517 ± 106 476 ± 31 
Lung (%) 1.27 ± 0.19 1.23 ± 0.09 
Heart (g) 169 ± 8 176 ± 4 
Heart (%) 0.436 ± 0.014 0.447 ± 0.016 
Right ventricle (g) 35.4 ± 2.3 37.4 ± 1.2 
Left ventricle (g) 61.2 ± 2.6 66.1 ± 3.7 
Liver (g) 597 ± 47 560 ± 24 
Liver (%) 1.50 ± 0.04 1.41 ± 0.03 
Kidneys (g) 100 ± 4 109 ± 7 
Kidneys (%) 0.257 ± 0.007 0.275 ± 0.013 
Spleen (g) 129 ± 19 135 ± 26 
Spleen (%) 0.334 ± 0.052 0.344 ± 0.071 
Visceral fat (g) 418 ± 90 514 ± 92 
Visceral fat (%) 1.07 ± 0.22 1.29 ± 0.21 
Data are mean ± SEM. Unless otherwise noted, organ weights given as % are relative to 718 
maternal body weight.  719 
  720 
Table 3. Mean normalised expression of molecules that regulate cardiac growth and 721 
metabolism in control and asthmatic ewes in late gestation. 722 
 Control (n=5) Allergic (n=7) 
Physiological hypertrophy 
  IGF1 0.058 ± 0.001 0.077 ± 0.015 
  IGF2 1.211 ± 0.102 1.200 ± 0.056 
  IGF1R  0.501 ± 0.010 0.480 ± 0.034 
Pathological hypertrophy 
  ANP   7.422 ± 4.696 0.485 ± 0.106 
  BNP  1.908 ± 1.161 0.356 ± 0.172 
  IGF2R  0.231 ± 0.012 0.257 ± 0.026 
  AT1R  0.044 ± 0.004 0.037 ± 0.003 
Cortisol availability  
  GR  0.535 ± 0.030 0.453 ± 0.027 
  MR  0.108 ± 0.003 0.100 ± 0.005 
  11βHSD1  0.015 ± 0.002 0.014 ± 0.001 
  11βHSD2  0.0009 ± 0.0002 0.0013 ± 0.0002 
Inflammation 
  TNF  0.020 ± 0.005 0.016 ± 0.004 
  IL1β  0.011 ± 0.003 0.006 ± 0.001 
Fibrosis 
  TGFβ  0.212 ± 0.046 0.284 ± 0.074 
  Collagen type II  0.003 ± 0.001 0.002 ± 0.001 
  MMP2  0.104 ± 0.012 0.083 ± 0.004 
  TIMP1  0.259 ± 0.039 0.208 ± 0.022 
  TIMP2  0.179 ± 0.007 0.214 ± 0.018 
  TIMP3  0.852 ± 0.089 0.955 ± 0.067 
Proliferation 
  PCNA  0.078 ± 0.005 0.072 ± 0.002 
  Ki67  0.006± 0.002 0.004 ± 0.001 
Glucose uptake 
  GLUT1  0.008 ± 0.001 0.011 ± 0.002 
  GLUT4  0.199 ± 0.014 0.269 ± 0.027 
Reactive oxygen stress 
  HO1  0.050 ± 0.008 0.044 ± 0.005 
Data are mean normalised expression ± SEM. 723 
  724 
Table 4. Placental phenotype and fetal size and organ weights at post-mortem. 725 
 726 
 Control (n=5) Allergic (n=7) 
Placenta 
Placental weight 344 ± 51 323 ± 23 
Total placentomes (no.) 76.4 ± 6.5 73.7 ± 4.7 
Average placentome weight (g) 4.39 ± 0.37 4.40 ± 0.21 
Fetal weight and size at post-mortem 
Body weight (kg) 4.11 ± 0.28 3.69 ± 0.14 
Crown-rump length (cm) 57.2 ± 0.9 56.1 ± 1.0 
Abdominal circ. (cm) 35.0 ± 1.2 33.0 ± 0.7 
Thoracic circ. (cm) 33.7 ± 1.0 32.1 ± 0.5 
Head length (cm) 12.9 ± 0.4 13.3 ± 0.4 
Head width (cm) 9.2 ± 0.1 9.4 ± 0.3 
Fetal organ weights at post-mortem 
Lung (g) 137 ± 12 137 ± 7 
Lung (%) 3.22 ± 0.14 3.72 ± 0.20 
Brain (g) 59.1 ± 1.0 57.3 ± 1.4 
Brain (%) 1.46 ± 0.10 1.56 ± 0.05 
Liver (g) 96.7 ± 11.1 86.9 ± 5.8 
Liver (%) 2.33 ± 0.12 2.35 ± 0.10 
Brain:liver ratio 0.64 ± 0.07 0.67 ± 0.04 
Heart (g) 27.7 ± 1.8 25.3 ± 1.2 
Heart (%) 0.674 ± 0.019 0.686 ± 0.022 
Kidneys (g) 24.0 ± 2.1 23.3 ± 0.9 
Kidneys (%) 0.582 ± 0.026 0.631 ± 0.012 
Spleen (g) 5.93 ± 0.78 6.07 ± 0.48 
Spleen (%) 0.144 ± 0.016 0.164 ± 0.012 
Visceral fat (g) 24.2 ± 3.2 23.7 ± 0.8 
Visceral fat (%) 0.580 ± 0.041 0.644 ± 0.016 
 727 
Data are mean ± SEM. Unless otherwise noted, organ weights given as % are relative to fetal 728 
body weight. Circ., circumference   729 
Figure legends 730 
 731 
Figure 1.  Study design. *Lost to study: 4 allergic and 4 control singleton-bearing ewes were 732 
lost to study due to non-pregnancy (detected at surgery; n= 1 allergic ewe), sick on farm (n= 733 
1 control), failure to recover post-surgery (n= 0 control, 1 allergic ewes), fetal death  (n= 1 734 
control, 0 allergic ewes) or premature delivery  (n= 2 control, n= 2 allergic ewes). 735 
 736 
Figure 2: Immune cell populations in BAL fluid before and 48 h after airway challenge. Data 737 
are numbers of (A) macrophages, (B) lymphocytes, (C) neutrophils and (D) eosinophils as a 738 
proportion of all immune cells and are shown as mean +- SEM. Control animals are shown in 739 
open bars, and allergic  animals in filled bars, samples collected prior to airway challenge in 740 
plain bars and samples collected 48 h after airway challenge are in hatched bars. Differences 741 
between control and allergic animals at the same time relative to challenge are shown by * 742 
P<0.05, ** P<0.01, and *** P<0.001, differences between pre- and 48h-post challenge 743 
values within a group at each gestational age are shown by $ P<0.05, $$ P<0.01, and $$$ 744 
P<0.001, and overall differences between gestational ages are indicated by ^ P<0.05. 745 
 746 
Figure 3. Responses to airway challenge in pregnancy. Mean percentage change from 747 
baseline lung resistance (RL) in allergic sheep challenged with HDM (filled circles) and 748 
control sheep challenged with saline (open circles), at early, mid and late stages in pregnancy. 749 
Results for each time point represent the group mean of the maximum change in resistance 750 
over the first 30 min after challenge. Differences between control and allergic animals at the 751 
same gestational age are shown by **, P<0.01. Difference in allergic animals at late 752 
pregnancy compared to early pregnancy is shown by ^, P<0.05. 753 
 754 
Figure 4.  Maternal lung tissue sections stained with Masson’s trichrome in (A) control and 755 
(B) allergic pregnant sheep, showing collagen (blue stained areas) and airway smooth muscle 756 
(black arrows) staining. Image analysis of Masson’s trichrome-stained lung sections for the 757 
quantitation of (C) airway smooth muscle (ASM) and (D) collagen content relative to 758 
basement membrane (BM) length. Anti-tryptase mast cell
+
 staining (white arrows; 759 
degranulated mast cells indicated with open arrows) in lung tissue of (E) control and (F) 760 
allergic pregnant sheep, with cell counts presented in (G) airway parenchyma, and (H) within 761 
the airway wall. Differences between control and allergic animals are shown by **, P<0.01. 762 
Quantitative data are presented as data from individual animals for control (open circles) and 763 
allergic (closed circles) sheep, with mean ± SEM (n=5/group).  764 
 765 
Figure 5. Effect of maternal asthma on (A) maternal body weight, (B) absolute fetal body 766 
weight, and (C) fetal body weight (relative to maternal weight) at ~140 dGA. Quantitative 767 
data are presented as data from individual animals for control (open circles) and allergic 768 
(closed circles) sheep, with mean ± SEM shown in bars. Differences between control and 769 
allergic animals are shown by *, P<0.05. 770 
 771 
Figure 6. Effect of maternal asthma on placental phenotype. Data are mean ± SEM. 772 
Differences between control and allergic animals are shown by *, P<0.05; #, 0.05<P<0.1. 773 
 774 
Figure 7. Effect of maternal allergy (black bars) on mRNA levels of surfactant proteins A, B, 775 
C and D in fetal lung. Data are presented as mean ± SEM, expressed relative to the control 776 
group (white bars) at each age. All data are corrected for the expression level of the reference 777 
gene Rps29. Differences between control and allergic animals are shown by *, P<0.05; #, 778 
P=0.05 779 
  780 
Figure 1.   781 
 782 
   783 
Random allocation
Randomised (n = 40 ewes)
CONTROL
Non-immunised





EWES (n = 4)
Assessment of allergic status
(≥2-fold increase in HDM-IgE)














Fetal and maternal catheterisation
Postmortem at 138-142 dGA
LOST TO STUDY*
(n = 4 CONTROL, 
4  ALLERGIC)
Weekly airway challenges with saline 
(CONTROL EWES) or 1 mg HDM in 




Basal serum sample for IgE, 3 sensitisations to HDM 
at 1 week intervals, serum sample 2 weeks later




Figure 2:  784 
785 
  786 
Figure 3.  787 
  788 
Figure 4.   789 
 790 
 791 
  792 
A B 
E F 
Figure 5.  793 
 794 
  795 
Figure 6.  796 
 797 
  798 
Figure 7.  799 
 800 
